A startup that spun out of research conducted at the University of Pittsburgh announced it appointed a CEO and that it has undergone a rebranding effort as it works to commercialize its investigative nerve repair technology.
Swan NeuroTech, previously Nerve Repair Technologies, has appointed Jeremy Kimmel as CEO. Its founder, Kacey Marra, takes on the role of chief scientific officer.
"Jeremy has a stellar track record of developing and commercializing innovative medical products," Marra said in a prepared statement. "His expertise in navigating complex regulatory and clinical markets will be invaluable to Swan NeuroTech as we continue to advance our portfolio of novel biomaterials for nerve healing and regeneration."
Kimmel joins the company after previously leading development efforts at South Side-based ALung Technologies, which global medical tech firm LivaNova acquired for $10 million in May 2022. He has over 15 years of experience in the medtech and biotech scene and played a key role in securing U.S. Food and Drug Administration approval for ALung's respiratory support device.
"I am truly grateful for the opportunity to join Swan NeuroTech and to help bring world-class regenerative therapies to patients across the world," Kimmel said in a prepared statement.
Marra founded the company in 2019. It has a licensed IP portfolio from Pitt that it is commercializing for peripheral nerve injuries. Swan NeuroTech's products are for investigative purposes, not clinical use, the company said.
